Document:

Exhibit 10.10

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850
7286

 

24
September 2017

 

Attn:
Dr. Mirko Scherer

 

Dear
Dr. Scherer,

 

Appointment
Letter for Independent Non-Executive Director

 

We
are pleased and welcome your acceptance to be appointed as an Independent Non-Executive Director of Aptorum Group Limited (the
“Company” , formerly known as Aptus Holdings Limited), a company incorporated with limited liabilities under the laws
of the Cayman Islands, with wholly owned subsidiaries in the Cayman Islands, Hong Kong, and Macau, whereby collectively, shall
be depicted as “Aptorum” or the “Group”.

 

The
following letter seeks to illustrate the context of your appointment by the Company, and the terms and conditions as set out herewith.
It is agreed that on acceptance of this offer, this letter will constitute a contract for services and not a contract of employment.

 

For
the purposes of independence, this letter will supersede all previous appointment contract or agreement, if applicable, entered
into between yourself and the Company (or its affiliated subsidiaries). By signing this letter and therefore accepting the appointment
as stated, you agree to terminate all other previous appointments with the Group commencing from the Effective Date.

 

		1.	The
                                         Company and the Group

 

Aptorum
focuses on the licensing of, and acquisition of early stage preclinical assets with the intention to engage in drug research,
development, and commercialization purposes. Assets are acquired via open and public platforms such as the technology transfer
offices of accredited universities and academic institutions. In addition, the Group seeks to be a facilitator across the financing
spectrum for biotech companies, entrepreneurs, and commercializing agents, to bolster innovations adding value to health care
needs in the marketplace; and to assist in furthering the research capabilities of institutions the Group works with.

 

The
Company is a privately held company that has engaged in plans to pursue an initial public offering on the Nasdaq Global Market
in the near future (the “Listing”).

 

		2.	Appointment

 

		(a)	You
                                         will be nominated by the Nominating Committee and appointed by the Board of Directors
                                         of the Company (the “Board”) to act as an Independent Non-Executive Director
                                         (“INED”) of the Company.

 

     

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850
7286

 

		(b)	To
                                         the extent required if the required quorum for the below committees is not reached for
                                         a board meeting, you shall agree to being appointed by the Board as a member and/or chair
                                         of the following committees:

 

		a.	Nominating
                                         and Corporate Governance Committee; and
	 	 	 

		b.	Compensation
                                         Committee.

 

Whereby
both committees shall collectively be depicted as the “Committees”; and roles for (a) and (b) (if relevant) shall
collectively be described as the “Appointment” or “Roles”.

 

		(c)	The
                                         Appointment is subject to the Company’s Memorandum and Articles of Association
                                         ("Articles") and nothing in this letter shall be taken to exclude or vary the
                                         terms of the Articles as they apply to your Appointment.

 

		(d)	The
                                         continuation of the Appointment is contingent to your ongoing fulfillment of your obligations
                                         and successful re-election by the Company’s shareholders at the Company’s
                                         Annual General Meeting (the “AGM”). It is further subject to your agreement
                                         to apply yourself and discharge your duties as a Non-Executive Director in accordance
                                         with the Articles of the Company and the Cayman Islands Company Law (2016 Revision) (as
                                         amended) ("Company Law"), as well as you upholding the high standards of corporate
                                         governance as set forth in the Nasdaq Listing Rule 5600 Series subsequent to the Listing.

 

	3.	Date
                                         of Commencement and Term

 

The
official commencement date of your Appointment shall be on 15 October 2017 (the “Effective Date”), or as mutually
agreed upon between yourself and the Executive Board of Directors of the Company. The Term of this Appointment shall be 3 years
from the Effective Date and subject to the terms of Termination and the re-election by the Company’s shareholders at
the AGM as set forth in 2(d) herein above.

 

		4.	Duties
                                         and Responsibilities

 

As
an INED of the Company:

 

		(a)	You
                                         have the same general legal responsibilities to the Company as any other Director and
                                         will advise where necessary, the Executive Board of Directors of the Company.

 

		(b)	You
                                         will exercise your powers of your Appointment having regard to the relevant obligations
                                         under prevailing law and regulation, including the Cayman Islands Company Law, and while
                                         in pursuit of and subsequent to the Listing, also the rules stipulated by the Nasdaq
                                         Regulatory Authority; including but not limited to the Listing Rule 5600 Series.

 

		(c)	You
                                         shall remain mindful and ensure your status of independence remains compliant as stipulated
                                         by requirements of Nasdaq Rule 5605(a)(2) and Securities Exchange Act Rule 10A-3. Should
                                         your independent status cease to remain compliant, you must notify the Board of the Company
                                         of such said change as soon as practical, and if subsequent to the Listing, notification
                                         must additionally be made to Nasdaq no later than the sooner of (i) the next annual shareholders
                                         meeting or (ii) one year from occurrence of the event causing failure to comply. You
                                         shall further facilitate any director independence disclosures in annual meeting proxy
                                         statements or annual report on Form 10-K, including transactions and arrangements considered
                                         by the Board in assessing director independence.

 

    2

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850
7286

 

		(d)	Subsequent
                                         to the Listing, you along with other Directors of the Board, are to meet when possible
                                         in executive session, where such sessions should occur at least four times a year. Additionally,
                                         you are to meet with other INEDs without executive management at least twice a year.

 

		(e)	Additionally,
                                         you may be sought within reason, to engage in ad hoc strategic discussions that may require
                                         you reviewing and execution of documents pertinent to Board decisions. Such meetings
                                         shall take place in person, or by telephone conferencing, at a sensible time of day in
                                         relation to your primary place of residence.

 

		(f)	You
                                         shall not directly be responsible for the management of the Company. Your role is neither
                                         operational nor managerial in nature however; members of the Executive Board may draw
                                         upon your professional insight and business expertise where suitable. You shall provide
                                         guidance, steering, and access of expert networks to the Company where appropriate and
                                         required.

 

Should
at any period within the Term you be appointed as a Chair and/or member of the said Committees described in Clause 2(b):

 

		(g)	You
                                         shall review and uphold the functions of your relevant committee(s) as pursuant to individually
                                         adopted Compensation, and Nominating and Corporate Governance Committee Charters (“Charters”)
                                         that shall be made available to you upon a practical date subsequent to your Appointment
                                         and before the Listing.

 

		(h)	You
                                         must along with other Committee members, review annually and assess the adequacy of the
                                         same said Charters.

 

		(i)	You
                                         must along with other Committee members, ensure compliance with Nasdaq listing rules
                                         at all times subsequent to the Listing with respect to Committee composition requirements,
                                         and assist the Company in regaining compliance if required by curing the event that caused
                                         failure to comply within the time frame provided by the Nasdaq Regulatory Authority.

 

		(j)	You
                                         must refrain from accepting any direct or indirect consulting, advisory, or other compensatory
                                         fee from the Company or the Group subsequent to the Listing, other than fees for director
                                         service as described more fully below in Clause 5.

 

Additionally,
you shall during the Term of your Appointment:

 

		(i)	Observe
                                         and comply with the Company’s adopted Code of Business Conduct and Ethics, where
                                         that any waivers given to directors or executive officers must be approved by the Board.

 

		(ii)	Observe
                                         and comply with all statutory rules, and regulations where applicable as governed by
                                         the laws of your residence;

 

    3

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850
7286

 

		(iii)	Confirm
                                         you are able to, and will devote sufficient time to perform your Roles.

 

		(iv)	Provide
                                         traceable contact during and after office hours, on weekdays and weekends, or during
                                         public holidays, whereby your availability may occasionally and reasonably be sought.

 

		(v)	Declare
                                         any conflicts that are apparent at present, or become apparent, between the Group and
                                         your other business interests. Should any potential conflicts of interest arise, you
                                         will disclose this to the Board as soon as they become apparent.

 

		(vi)	Consult
                                         with the Chairman of the Board prior to accepting any other (or further) directorships
                                         of publicly quoted companies or any major external appointments.

 

		(vii)	Obtain
                                         clearance from the Chairman of the Board prior to dealing in publicly traded shares in
                                         the Company subsequent to the Listing.

 

		(viii)	Observe
                                         and comply with the disclosure requirements and obligations of you and/or your affiliated
                                         party(s) as applicable in accordance with U.S. securities laws, regulations and SEC disclosure
                                         requirements.

 

		5.	Fees
                                         and Expenses

 

		(a)	The
                                         basic fee for being an INED of the Company is USD 30,000 per annum (U.S. Dollars
                                         Thirty Thousand), paid to you by the Company in arrears in twelve monthly installments
                                         on or about the last business day of each month.

 

		(b)	You
                                         will be entitled to bonus during the Appointment and entitled to participate in any share
                                         plan operated by the Company. You will also be entitled to an increase in basic fees
                                         during the Appointment. For the avoidance of doubt, your entitlement as stated in this
                                         paragraph is in relation to your capacity as independent non-executive director only.

 

		(c)	The
                                         Company will reimburse all reasonable travelling, hotel and other expenses incurred by
                                         you in connection with the Company’s business on production of appropriate receipts.

 

		6.	Privacy
                                         of Information

 

		(a)	You
                                         shall not except as authorized by the Group or required by your responsibilities reveal
                                         to any person or company any of the trade secrets or any information concerning the organization,
                                         business, finances, transactions or affairs of the Group which may come to your knowledge
                                         during your contract with the Company and shall keep with complete secrecy confidential
                                         information entrusted to you and shall not use or attempt to use any such information
                                         in any manner which may injure or cause loss either directly or indirectly to the Group
                                         or may be likely to do so. This restriction shall continue to apply if and when after
                                         the termination of your appointment without limit in time.

 

    4

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850
7286

 

		(b)	You
                                         shall not either during the period of your Appointment or afterwards use or permit to
                                         be used any books, documents, moneys, assets, records or other property belonging to
                                         or relating to any dealings, affair or business of the Group other than for the benefit
                                         of the Group. You shall immediately deliver and return to the Group all such books, documents,
                                         moneys, securities, records or other property which you then have or should have in your
                                         possession upon termination of your Appointment hereunder.

 

		(c)	The
                                         Company however, agrees to provide you in good faith with any information concerning
                                         areas of interest and relevance of the Group as required by you in order to enable you
                                         to fulfill your Roles with the Company.

 

		7.	Data
                                         Protection

 

		(a)	By
                                         executing this letter, you consent to the Company holding and processing information
                                         about you for legal, personnel, administrative, and management purposes and in particular
                                         to the processing of any sensitive personal data as and when appropriate.

 

		(b)	You
                                         consent to the transfer of such personal information to other offices the Company may
                                         have or to other third parties for administrative purposes and other purposes in connection
                                         with the Appointment, where it is necessary or desirable to do so.

 

		8.	Insurance
                                         and Indemnity

 

The
Company shall establish directors’ and officers’ liability coverage and it is intended to maintain such coverage for
the full term of the Appointment.

 

		9.	Termination

 

Your
Appointment with respect to the Roles with the Company may only be terminated:

 

		(a)	By
                                         you after giving the Company not less than two (2) months’ notice in writing;

 

		(b)	By
                                         the Company after giving you two (2) months’ notice in writing; or

 

		(c)	By
                                         the Company with immediate effect in the event that you:

 

		(i)	Conduct
                                         dishonesty, fraud, gross negligence, willful default or refusal to carry out any lawful
                                         order or instructions, or the repeated breach of any rules or regulations of the Company,
                                         or those as governed by the laws of your residency;

 

		(ii)	Commit
                                         a material breach of your obligations under this letter;

 

    5

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850
7286

 

		(iii)	Commit
                                         any serious or repeated breach or non-observance of your obligations to the Company;

 

		(iv)	Are
                                         convicted of a criminal offence other than an offence under road traffic legislation
                                         in the jurisdiction of your residency or elsewhere for which a fine or non-custodial
                                         penalty is imposed;

 

		(v)	Declare
                                         bankruptcy or have made an arrangement with or for the benefit of your creditors; or

 

		(vi)	Are
                                         disqualified from acting as a director.

 

Please
signify your acceptance of the above terms and conditions by signing and returning to us the enclosed duplicate copy of this letter.

 

Yours
faithfully, 

 

For
and on behalf of

 

	APTORUM GROUP LIMITED	 	Agreed and accepted by:
	 	 	 
	 	 	 
	Name: Huen Chung Yuen Ian	 	Name: Dr. Mirko Scherer
	Position: Director	 	 
	 	 	 
	 	 	 
	Date	 	Date

 

    6Exhibit 10.11

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850 7286

 

18
September 2017

 

Attn:
Dr. Wu Che Yuen Justin

  

Dear
Dr. Wu,

 

Appointment
Letter for Independent Non-Executive Director

 

We
are pleased and welcome your acceptance to be appointed as an Independent Non-Executive Director of Aptorum Group Limited (the
“Company”), a company incorporated with limited liabilities under the laws of the Cayman Islands, with wholly owned
subsidiaries in the Cayman Islands, Hong Kong, and Macau, whereby collectively, shall be depicted as “Aptorum” or
the “Group”.

 

The
following letter seeks to illustrate the context of your appointment by the Company, and the terms and conditions as set out herewith.
It is agreed that on acceptance of this offer, this letter will constitute a contract for services and not a contract of employment.

 

For
the purposes of independence, this letter will supersede all previous appointment contract or agreement, if applicable, entered
into between yourself and the Company (or its affiliated subsidiaries). By signing this letter and therefore accepting the appointment
as stated, you agree to terminate all other previous appointments with the Group commencing from the Effective Date.

 

		1.	The
                                         Company and the Group

 

Aptorum
focuses on the licensing of, and acquisition of early stage preclinical assets with the intention to engage in drug research,
development, and commercialization purposes. Assets are acquired via open and public platforms such as the technology transfer
offices of accredited universities and academic institutions. In addition, the Group seeks to be a facilitator across the financing
spectrum for biotech companies, entrepreneurs, and commercializing agents, to bolster innovations adding value to health care
needs in the marketplace; and to assist in furthering the research capabilities of institutions the Group works with.

 

The
Company is a privately held company that has engaged in plans to pursue an initial public offering on the Nasdaq Global Market
in the near future (the “Listing”).

 

		2.	Appointment

 

		(a)	You
                                         will be nominated by the Nominating Committee and appointed by the Board of Directors
                                         of the Company (the “Board”) to act as an Independent Non-Executive Director
                                         (“INED”) of the Company.

 

     

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850 7286

 

		(b)	You
                                         shall agree to being appointed by the Board as a member and/or chair of the following
                                         committees:

 

		a.	Chair
                                         and member of the Compensation Committee;

		b.	Member
                                         of the Audit Committee; and

		c.	Member
                                         of the Nominating and Corporate Governance Committee;

 

Whereby
all three committees shall collectively be depicted as the “Committees”; and roles for (a) and (b) shall collectively
be described as the “Appointment” or “Roles”.

 

		(c)	The
                                         Appointment is subject to the Company’s Memorandum and Articles of Association
                                         ("Articles") and nothing in this letter shall be taken to exclude or vary the
                                         terms of the Articles as they apply to your Appointment.

 

		(d)	The
                                         continuation of the Appointment is contingent to your ongoing fulfillment of your obligations
                                         and successful re-election by the Company’s shareholders at the Company’s
                                         Annual General Meeting (the “AGM”). It is further subject to your agreement
                                         to apply yourself and discharge your duties as a Non-Executive Director in accordance
                                         with the Articles of the Company and the Cayman Islands Company Law (2016 Revision) (as
                                         amended) ("Company Law"), as well as you upholding the high standards of corporate
                                         governance as set forth in the Nasdaq Listing Rule 5600 Series subsequent to the Listing.

 

		3.	Date
                                         of Commencement and Term

 

The
official commencement date of your Appointment shall be on 15 October 2017 (the “Effective Date”), or as mutually
agreed upon between yourself and the Executive Board of Directors of the Company. The Term of this Appointment shall be 3 years
from the Effective Date and subject to the terms of Termination and the re-election by the Company’s shareholders at
the AGM as set forth in 2(d) herein above.

 

		4.	Duties
                                         and Responsibilities

 

As
an INED of the Company:

 

		(a)	You
                                         have the same general legal responsibilities to the Company as any other Director and
                                         will advise where necessary, the Executive Board of Directors of the Company.

 

		(b)	You
                                         will exercise your powers of your Appointment having regard to the relevant obligations
                                         under prevailing law and regulation, including the Cayman Islands Company Law, and while
                                         in pursuit of and subsequent to the Listing, also the rules stipulated by the Nasdaq
                                         Regulatory Authority; including but not limited to the Listing Rule 5600 Series.

 

		(c)	You
                                         shall remain mindful and ensure your status of independence remains compliant as stipulated
                                         by requirements of Nasdaq Rule 5605(a)(2) and Securities Exchange Act Rule 10A-3. Should
                                         your independent status cease to remain compliant, you must notify the Board of the Company
                                         of such said change as soon as practical, and if subsequent to the Listing, notification
                                         must additionally be made to Nasdaq no later than the sooner of (i) the next annual shareholders
                                         meeting or (ii) one year from occurrence of the event causing failure to comply. You
                                         shall further facilitate any director independence disclosures in annual meeting proxy
                                         statements or annual report on Form 10-K, including transactions and arrangements considered
                                         by the Board in assessing director independence.

 

    2

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850 7286

 

		(d)	Subsequent
                                         to the Listing, you along with other Directors of the Board, are to meet when possible
                                         in executive session, where such sessions should occur at least four times a year. Additionally,
                                         you are to meet with other INEDs without executive management at least twice a year.

 

		(e)	Additionally,
                                         you may be sought within reason, to engage in ad hoc strategic discussions that may require
                                         you reviewing and execution of documents pertinent to Board decisions. Such meetings
                                         shall take place in person, or by telephone conferencing, at a sensible time of day in
                                         relation to your primary place of residence.

 

		(f)	You
                                         shall not directly be responsible for the management of the Company. Your role is neither
                                         operational nor managerial in nature however; members of the Executive Board may draw
                                         upon your professional insight and business expertise where suitable. You shall provide
                                         guidance, steering, and access of expert networks to the Company where appropriate and
                                         required.

 

As
the Chair and/or member of the said Committees described in Clause 2(b):

 

		(g)	You
                                         shall review and uphold the functions of your relevant committee(s) as pursuant to individually
                                         adopted Audit, Compensation, and Nominating and Corporate Governance Committee Charters
                                         (“Charters”) that shall be made available to you upon a practical date subsequent
                                         to your Appointment and before the Listing.

 

		(h)	You
                                         must along with other Committee members, review annually and assess the adequacy of the
                                         same said Charters.

 

		(i)	You
                                         must along with other Committee members, ensure compliance with Nasdaq listing rules
                                         at all times subsequent to the Listing with respect to Committee composition requirements,
                                         and assist the Company in regaining compliance if required by curing the event that caused
                                         failure to comply within the time frame provided by the Nasdaq Regulatory Authority.

 

		(j)	You
                                         must refrain from accepting any direct or indirect consulting, advisory, or other compensatory
                                         fee from the Company or the Group subsequent to the Listing, other than fees for director
                                         service as described more fully below in Clause 5.

 

		(k)	Additionally
                                         as an Audit Committee member, you must refrain from participating in preparation of financial
                                         statements of the Company or the Group. However, along with other members you shall be
                                         directly responsible for appointing and terminating the Company’s independent auditor(s).

 

		(l)	You
                                         shall maintain your financial literacy and expertise requirements in order to maintain
                                         your individual financial sophistication and qualify as an Audit Committee member.

 

    3

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850 7286

 

		(m)	You
                                         shall assist the Audit Committee in review of related person transactions and conducting
                                         oversight for potential conflict of interest situations on an ongoing basis, and more
                                         generally, oversight with respect to the code of conduct compliance by senior management
                                         of the Company.

 

Additionally,
you shall during the Term of your Appointment:

 

		(i)	Observe
                                         and comply with the Company’s adopted Code of Business Conduct and Ethics, where
                                         that any waivers given to directors or executive officers must be approved by the Board.

 

		(ii)	Observe
                                         and comply with all statutory rules, and regulations where applicable as governed by
                                         the laws of your residence;

 

		(iii)	Confirm
                                         you are able to, and will devote sufficient time to perform your Roles.

 

		(iv)	Provide
                                         traceable contact during and after office hours, on weekdays and weekends, or during
                                         public holidays, whereby your availability may occasionally and reasonably be sought.

 

		(v)	Declare
                                         any conflicts that are apparent at present, or become apparent, between the Group and
                                         your other business interests. Should any potential conflicts of interest arise, you
                                         will disclose this to the Board as soon as they become apparent.

 

		(vi)	Consult
                                         with the Chairman of the Board prior to accepting any other (or further) directorships
                                         of publicly quoted companies or any major external appointments.

 

		(vii)	Obtain
                                         clearance from the Chairman of the Board prior to dealing in publicly traded shares in
                                         the Company subsequent to the Listing.

 

		(viii)	Observe
                                         and comply with the disclosure requirements and obligations of you and/or your affiliated
                                         party(s) as applicable in accordance with U.S. securities laws, regulations and SEC disclosure
                                         requirements.

 

		5.	Fees
                                         and Expenses

 

		(a)	The
                                         combined basic fee for being an INED of the Company and your roles as chair and/or member
                                         of relevant Committees is USD 30,000 per annum (U.S. Dollars Thirty Thousand),
                                         paid to you by the Company in arrears in twelve monthly installments on or about the
                                         last business day of each month.

 

		(b)	You
                                         will be entitled to bonus during the Appointment and entitled to participate in any share
                                         plan operated by the Company. You will also be entitled to an increase in basic fees
                                         during the Appointment. For the avoidance of doubt, your entitlement as stated in this
                                         paragraph is in relation to your capacity as independent non-executive director only.

 

    4

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850 7286

 

		(c)	The
                                         Company will reimburse all reasonable travelling, hotel and other expenses incurred by
                                         you in connection with the Company’s business on production of appropriate receipts.

 

		6.	Privacy
                                         of Information

 

		(a)	You
                                         shall not except as authorized by the Group or required by your responsibilities reveal
                                         to any person or company any of the trade secrets or any information concerning the organization,
                                         business, finances, transactions or affairs of the Group which may come to your knowledge
                                         during your contract with the Company and shall keep with complete secrecy confidential
                                         information entrusted to you and shall not use or attempt to use any such information
                                         in any manner which may injure or cause loss either directly or indirectly to the Group
                                         or may be likely to do so. This restriction shall continue to apply if and when after
                                         the termination of your appointment without limit in time.

 

		(b)	You
                                         shall not either during the period of your Appointment or afterwards use or permit to
                                         be used any books, documents, moneys, assets, records or other property belonging to
                                         or relating to any dealings, affair or business of the Group other than for the benefit
                                         of the Group. You shall immediately deliver and return to the Group all such books, documents,
                                         moneys, securities, records or other property which you then have or should have in your
                                         possession upon termination of your Appointment hereunder.

 

		(c)	The
                                         Company however, agrees to provide you in good faith with any information concerning
                                         areas of interest and relevance of the Group as required by you in order to enable you
                                         to fulfill your Roles with the Company.

 

		7.	Data
                                         Protection

 

		(a)	By
                                         executing this letter, you consent to the Company holding and processing information
                                         about you for legal, personnel, administrative, and management purposes and in particular
                                         to the processing of any sensitive personal data as and when appropriate.

 

		(b)	You
                                         consent to the transfer of such personal information to other offices the Company may
                                         have or to other third parties for administrative purposes and other purposes in connection
                                         with the Appointment, where it is necessary or desirable to do so.

 

		8.	Insurance
                                         and Indemnity

 

The
Company shall establish directors’ and officers’ liability coverage and it is intended to maintain such coverage for
the full Term of the Appointment.

 

    5

     

    

 

Aptorum Group Limited

Unit B, 17/F Guangdong Investment Tower,
148 Connaught Road Central, Hong Kong

Tel: (852) 2117 6611 ● Fax: (852) 2850 7286

 

		9.	Termination

 

Your
Appointment with respect to the Roles with the Company may only be terminated:

 

		(a)	By
                                         you after giving the Company not less than two (2) months’ notice in writing;

 

		(b)	By
                                         the Company after giving you two (2) months’ notice in writing; or

 

		(c)	By
                                         the Company with immediate effect in the event that you:

 

		(i)	Conduct
                                         dishonesty, fraud, gross negligence, willful default or refusal to carry out any lawful
                                         order or instructions, or the repeated breach of any rules or regulations of the Company,
                                         or those as governed by the laws of your residency;

 

		(ii)	Commit
                                         a material breach of your obligations under this letter;

 

		(iii)	Commit
                                         any serious or repeated breach or non-observance of your obligations to the Company;

 

		(iv)	Are
                                         convicted of a criminal offence other than an offence under road traffic legislation
                                         in the jurisdiction of your residency or elsewhere for which a fine or non-custodial
                                         penalty is imposed;

 

		(v)	Declare
                                         bankruptcy or have made an arrangement with or for the benefit of your creditors; or

 

		(vi)	Are
                                         disqualified from acting as a director.

 

Please
signify your acceptance of the above terms and conditions by signing and returning to us the enclosed duplicate copy of this letter.

 

Yours
faithfully, 

 

For
and on behalf of

 

	APTORUM GROUP LIMITED	 	Agreed and accepted by:
	 	 	 
	 	 	 
	Name: Huen Chung Yuen Ian	 	Name: Wu Che Yuen Justin
	Position: Director	 	 
	 	 	 
	 	 	 
	Date	 	Date

 

    6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]